Zeliha Chaffin
(The World)
Published on September 30, 2024 at 07:28.
Between the Danish Novo Nordisk and the American Lilly, the battle over anti-obesity drugs is accelerating. In November 2023, the Indianapolis laboratory received the green light in the United States for the marketing of its weight loss treatment, Zepbound. The latter becomes the direct competitor of Wegovy (called Ozempic in its original version), Novo Nordisk’s best-seller. The pressure is mounting between the two rivals, neck and neck in the fray.
The duo is not at their first face-to-face meeting. A century ago, the arrival of insulins, a revolution in the treatment of diabetes, had already opened a front line between manufacturers. A hundred years later, the diabetes bonanza continues to make their fortune, but it is in another area, that of obesity, that the two groups are intensifying their efforts thanks to a new generation of promising treatments.
Want to read all of our articles?
For CHF 29.- per month, enjoy unlimited access to our articles, without obligation!
I subscribe
Good reasons to subscribe to Le Temps:
- Unlimited access to all content available on the website.
- Unlimited access to all content available on the mobile application
- Sharing plan of 5 articles per month
- Consultation of the digital version of the newspaper from 10 p.m. the day before
- Access to supplements and T, the Temps magazine, in e-paper format
- Access to a set of exclusive benefits reserved for subscribers
Already a subscriber?
Log in
